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REVIEW

siRNA Targeting and Treatment of Gastrointestinal
Diseases
Rachel Chevalier1,2,*

RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the
GI tract proves challenging as the harsh environment of the intestines degrades the siRNA before it can reach its target or
blocks its entry into its site of action in the cytoplasm. Additionally, the GI tract is large and disease is often localized to a
specific site. This review discusses polymer and lipid-based delivery systems for protection and targeting of siRNA therapies
to the GI tract to treat local disease.
Over the past decade, interest in siRNA therapy has grown
and expanded in scope. Building on the discovery of RNA
interference in 1998,1 specific oligonucleotides are now
synthetically derived to target specific genes for silencing,
expanding options for treatment of disease. The RNA interference pathway works by increasing the degradation and,
thus, decreasing the translation of unwanted messenger
RNA (mRNA) sequences. siRNA is a 19–23–base pair nucleotide sequence designed to reach the cell cytoplasm and
once there, binds with the RNA-induced silencing complex
(RISC).2–4 Binding with the RISC leads to degradation of the
sense strand, whereas the antisense strand continues to
be incorporated in the RISC. The RISC then makes multiple
mRNA cleavages to downregulate single gene expression.5
This narrow therapeutic mechanism is promising for diseases where current treatments too broadly affect the body
by suppressing the immune system, damaging off-target
organs, or inducing immune reactions. For therapeutic purposes, siRNA can be designed to target mRNA sequences
coding faulty proteins, proinflammatory cytokines, etc.
Diseases that affect the cells and tissue lining the gastrointestinal (GI) tract are common and include inflammatory
bowel disease (IBD), celiac disease, malignancy, gastroesophageal reflux disease, eosinophilic esophagitis, and
more. The GI tract can be considered “outside the body” in
that it is accessible without injection or incision and is not
a sterile environment. Therefore, targeting drugs to the GI
tract can be accomplished via oral, rectal, or endoscopic
methods, which can decrease the unnecessary systemic
exposure and associated adverse effects of parenteral medications. Administering siRNA via these methods is desirable, but delivery to the GI tract encounters many barriers.
The GI tract’s physiological function is to break down ingested contents and absorb nutrients while barricading the
body from invasion of toxins, foreign objects, and pathogens.6 The milieu of enzymes, fluids, and pH of the GI tract
are harsh to short nucleotide sequences, such as siRNA,

1

and quickly degrade them.7 Additionally, the GI tract is an
excellent barrier to the uptake of foreign substances that
are not obvious nutrients. The tight junctions between the
epithelial cells prevent paracellular passage of intestinal
contents.8 The mucous layer, stratified into loosely adherent and tightly adherent layers, prevents many substances
from making contact with the epithelial cells.9 Even if siRNA
manages to reach the GI epithelium intact, naked siRNAs
have a large molecular weight (~13 kDa) and large negative
charge, which hinders their ability to be taken up into the cell
into the cytoplasm where they must be present to exert their
effect.10 Additionally, unmodified siRNAs have the potential
to induce unwanted immunostimulatory effects, such as the
production of inflammatory cytokines.11,12
In an attempt to overcome these challenges, researchers
are developing methods to protect siRNA and deliver it the
appropriate areas of the GI tract. Direct delivery bypasses
metabolism in the serum and prevents off-targeting effects
that can arise when the medication is delivered systemically.
Thus, lower doses can be used and systemic toxicity can be
avoided. Methods to improve direct delivery to GI tissues
include chemical modifications to the siRNA molecule, protective shells, coatings, and particles, and components designed to target the diseased areas. The focus of this review
is these systems developed for delivery directly to the GI
tract tissues via oral, rectal, or endoscopic methods.
siRNA CHEMICAL MODIFICATIONS
Degradation of the siRNA in the intestinal lumen prior to
reaching the area of interest is the first barrier to successful
delivery. Discovery that modification of the 2′-OH group of
the RNA ribose affects recognition by ribonucleases13 led
researchers to begin substituting different groups at this
location with the aim to stabilize the RNA in vivo. Changing
to a 2′-O-methyl group increases efficacy of target gene
silencing and reduces off-target silencing14 –patirisan, the
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first US Food and Drug Administration (FDA) approved RNA
interference-based medication, contains a 2′-OMe modification.15 Modification to a 2′-F group increases serum stability and binding affinity of the siRNA duplex.16 Both the
O-methyl and the fluorine modifications decrease immunostimulation in mice,16 possibly due to modification of regions recognized by the toll-like receptors (TLRs) thought to
be responsible for this immunostimulation.11 Replacement
with DNA (2′-OH modified to 2′-H) at the 5′ end of the RNA
strand does not affect its RNA interference activity but confers stability.17 “Locked nucleic acids” (LNAs), which have
a methylene bridge between the 2′-O and the 4′-C, have
also been shown to increase stability to nuclease digestion
as well as reduce off-target effects and immunogenicity,18
although the location and extent of the modification matters—siRNA with seven LNAs at the 5′- end was less able to
associate with the Argonaut protein than siRNA with three
LNAs.17
RNA nucleotides can also be modified at the nonbridging
oxygen of the phosphodiester backbone. Replacement of
sulfur for the nonbridging oxygen blocks exonuclease activity and increases binding to plasma proteins preventing
rapid renal clearance.19 Further research into modifications
at sites, such as the ribose 4′-C, are underway.20
Ocampo et al.21 investigated various siRNA modifications
(2′-O-methylation, LNAs, phosphorothioate linkages, and
propanediol modification at the 3′ end) and their ability to
silence tumor necrosis factor-alpha (TNF-α) mRNA production in murine peritoneal exudate macrophages. Propanediol
modification of the 3′- end combined with a double methylation of the 5′- end on the TNF-α siRNA (siTNF-OMe-P)
was most effective at silencing TNF-α than either unmodified
TNF-α siRNA or any other chemical modifications tested. In
a fetal bovine serum degradation assay, the siTNF-OMe-P
proved the most stable at 24 hours of all those tested.
Dextran sodium sulfate (DSS) colitis mice were administered
siTNF-OMe-P suspended in media in 2 doses over 4 days.
The mice administered siTNF-OMe-P solution showed similar TNF-α protein levels to healthy mice and improved gross
colon appearance and decreased myeloperoxidase (MPO)
levels. However, the weight loss among mice was similar
across all treatments. Gene heat mapping of colon tissue
treated with siTNF-OMe-P demonstrated an increase in the
expression of tissue repair genes Claudin-7 and ssh2 compared with controls and similar levels of healthy epithelium
genes. To look at immune response, cultures of peripheral
blood mononuclear cells were exposed to the various siRNA
modifications. Levels of h-TNF-α, a marker of TLR activation
that is directly inhibited by TNF-α siRNA, were reduced in
all modified siRNA conditions in vitro. For the DSS colitis
mice treated with siTNF-OMe-P, TLR 2, 3, 4, 7, and 8 gene
expression was significantly downregulated compared with
controls. Single 2′-O-methylation showed no effect on the
TLR levels.
ORAL DELIVERY SYSTEMS
Oral therapies are preferred over other delivery methods
due to their ease of administration, safety profile, and improved compliance.22,23 The most frequently targeted
Clinical and Translational Science

intestinal disease for oral siRNA therapy is IBD, an autoimmune condition that is usually divided into two types:
ulcerative colitis and Crohn disease. Both versions cause
chronic, relapsing inflammation of the bowels with one distinction that ulcerative colitis is isolated to the mucosal surface of the colon, whereas Crohn disease can affect any
part of the GI tract from mouth to anus. Additionally, Crohn
disease is transmural, can be discontinuous, and can cause
fistulizing or stricturing disease. The intricate physiology of
IBD is still under investigation but thus far seems to have a
polygenic genetic susceptibility and is affected by external environmental factors and intestinal microbiota.24,25 IBD
presents with gastrointestinal symptoms, such as abdominal pain, weight loss, diarrhea, blood in stool, intestinal abscesses, and perianal fistulas (Crohn disease), as well as
extraintestinal manifestations, including skin lesions, blood
clots, and anemia. Biopsies obtained from patients with active disease show histopathological signs of inflammatory
cell infiltrate with mucosal and transmural injury, including
edema, loss of mucous-producing goblet cells, crypt cell
hyperplasia, crypt abscesses, crypt architecture distortion,
and ulcerations.26
Treatment for IBD is multidimensional and includes multiple targets. One of the most effective treatments in recent
years for moderate to severe disease is immunosuppressants aimed at TNF. TNF is produced by macrophages in
response to immune activation and has been found to have
a role in regulatory peptide expression in IBD.27 TNF antagonist agents, such as infliximab, adalimumab, and golimumab, use monoclonal antibodies to bind soluble TNF
in the serum.28 They may also bind precursor cell-surface
TNF leading to monocyte apoptosis.29 Certolizumab, another successful treatment, is the antigen-binding fragment (Fab’) of a humanized monoclonal antibody coupled
to polyethylene glycol. Unfortunately, infliximab and similar medications require frequent injections leading to pain
and patient noncompliance. Additionally, they come with
significant side effects, such as serious infections,30 immunosensitivity infusion reactions,31 injection site reactions,32
neutropenia,33 and possibly malignancy.34 However, given
their efficacy, TNF is a frequent target for oral siRNA therapy for IBD.
Polymer systems
Lipid based transfection agents are commercially available (e.g., Oligofectamine35 and Lipofectamine36) and have
been used in siRNA silencing. However, due to their unfavorable toxicity profile,37,38 some researchers are using
cationic polymers to protect siRNA payloads and increase
cellular uptake (Table 1). siRNA delivery systems are taken
up by the cell via endocytosis.39 The siRNA must then escape from the endosomes in order to join with the RISC.
Cationic lipids destabilize endosomal membranes by inducing nonbilayer lipid structures leading to escape of the
nucleic acid strands into the cytosol.40 Cationic polymers
are hypothesized to promote endosomal escape through
the “proton sponge” mechanism, wherein the increase in
ionic concentration leads to an osmotic swelling of the endosome and pronation of the polymer increases its internal
charge repulsion. When happening simultaneously, these
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Table 1 Summary of siRNA drug delivery methods to the gastrointestinal tract

Study

Year

siRNA
complex

Key components

Particle size

Site

In vitro cells

Target

Aouadi et al.42

2009

PEI

β1,3-D-glucan shells

2–4 μm

Oral

PEC MPs

Map4k4

20 μg/kg

Wilson et al.45

2010

DOTAP

PPADT

600 nm

Oral

RAW 264.7 MPs

TNF-α

23.0 μg siRNA/mL in vitro
2.3 mg/kg or 0.23 mg/kg
in vivo

Laroui et al.55

2011

PEI
Chitosan

PLA
PVA

380 nm

Oral

RAW 264.7 MPs

TNF-α

—

Xiao et al.51

2014

PEI

CD98 Ab
PEG
Chitosan

—

Oral

Colon-26
RAW 264.7 MPs
BMDM

CD98

100 nM in vitro
1 mg/kg in vivo

Xiao et al.52

2013

PEI

p(CBA-PEI)
PEG
Mannose

211–275 nm

Oral

RAW 264.7 MPs
Caco-2

TNF-α

100/200/300 nM (in vitro)

Laroui et al.54

2014

PEI

PLA
PVA

480 nm

Oral

N/A

CD98

In vitro: 200 μg/mL
In vivo: 1 mg/mL

Xiao et al.60

2016

Spermidine

PLGA
PVA
Chitosan

246 nm

Oral

Colon-26
RAW 264.7 MPs

CD98TNF-α

Laroui et al.71

2014

PEI

PLA
PEG
Maleimide
PVA
Fab’

376 nm (± 19) nm

Oral

RAW 264.7 MPs
U937 MPs
THP-1 MPs

TNF-α

In vivo: 60 μg/kg

Xiao et al.65

2018

Spermidine

PLGA
PVA
Chitosan
Galactose

261.3 ± 5.6 nm

Oral

Colon-26
RAW 264.7 MPs

TNF-α

In vitro: 5, 10, 15, 20 ng/mL
In vivo: 20 μg/kg
50 μg/kg IL-22

He et al.84

2013

None

TCC
TPP

118–153 nm

Oral

Caco-2
PEC MPs

TNF-α

In vitro: 0.4 μg/mL
In vivo: 200 μg/kg

Kriegel and
Amiji78

2011

None

Gelatin
PCL

2–4 μm

Oral

N/A

Attarwala
et al.81

2017

None

Gelatin

217.3 ± 8.4 nm

Oral

Caco-2
J774A.1

TG2
IL-15
TNF-α
IFN-γ

—

BallarínGonzález et
al.83

2013

None

Chitosan

124–129 nm

Oral

N/A

N/A

78 μg

Knipe et al.86

2016

None

Oral

RAW 264.7 MPs

TNF-α

110–112 nM

Ball et al.91

2018

Cholesterol

Lipidoids

~140 nm

Oral/Rectal

Caco-2HeLa

GAPDH

In vitro: 2,000, 1,000, 400,
or 100 nM
In vivo: 5 mg/kg

Zhang et al.92

2017

None

Ginger lipids

189.5 nm

Oral

CD98

In vitro: 30 nM
In vivo: 3.3 nmol × 2 doses

None

DEPC water

N/A

Rectal

N/A

TNF-α

100 ng per dose
2 doses per day × 6 days

McCarthy et al.95 2013

PEI

Cyclodextrin

~240 nm

Rectal

RAW 264.7 MPs

TNF-α

In vitro: 100 nmol/well in
24 well plate
In vivo: 50 μg

Frede et al.96

2016

PEI

Calcium phosphate
PLGA
PVA

~150 nm

Rectal

MODE-K
Colon organoids

TNF-α
KC
IP-10

12 μg

Sato et al.100

2017

None

Saline

N/A

Esophageal

N/A

CHST15

100 mg

Kim et al.103

2014

N/A

Chol-R9

N/A

Esophageal

A7r59L

MMP-9

60 μM

Schoellhammer
et al.94

P(MAA-co-NVP)
∼110 to ∼122 nm
DEAEMA-co-tBM A

Caco-2BBE
RAW 264.7
MPsColon-26

Cyclin
D1TNF-α

siRNA Dose

In vitro: 5–15 ng/mL;
4.1–12.3 μM
In vivo: 5 mg/kg curcumin;
16.55 μg/kg siRNA

1.2 mg/kg

BMDM, bone marrow–derived macrophages; Chol-R9, cholesteryl oliga-d-arginine; DEAEMA-co-tBMA, 2-(diethylamino)ethyl methacrylate-co-tert-butyl
methacrylate; DEPC, diethyl pyrocarbonate; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; Fab’, antigen-binding fragment; GAPDH, Glyceraldehyde
3-phosphate dehydrogenase; HA, hyaluronic acid; IFN, interferon; IL, interleukin; KC, keratinocide-derived cytokine; MMP-9, matrix malloproteinaise-9; MPs,
macrophages; N/A, not applicable; p(CBA-bPEI), p(Cystamine bisacrylamide-polyethylenimine); p(MAA-co-NVP), poly(methacrylic acid-co-N-vinyl-2-pyrrolidone); PBMC, peripheral blood mononuclear cell; PCL, polycaprolactone; PEC, peritoneal exudate cell; PEG, poly(ethylene glycol); PEI, polyethylenimine;
PLA, polylactide; PLGA, poly lactic-co-glycolic acid; PPADT, poly-(1,4-phenylaeneacteone dimethylene thioketal); PVA, polyvinyl alcohol; TCC, trimethyl
chitosan-cysteine; TG2, transglutaminase 2; TNF-α, tumor necrosis factor alpha; TPP, tripolyphosphate; tRNA, yeast transfer RNA.
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two factors theoretically lead to opening of the endosome,
although there have been studies that do not reflect this
mechanism.41
The first instance of oral siRNA delivery for IBD is seen in the
Aouadi et al.42 work in 2009. This group made 1,3-d-glucan
shells via solvent extraction of baker’s yeast. The shells were
filled with unmodified siRNA bound between layers of the cationic polymer polyethylenimine (PEI) and termed the product
glucan-encapsulated siRNA particles (GeRPs) (Figure 1a).
The GeRPs were loaded with siRNA against Map4k4, a germinal center protein kinase involved in TNF-α signaling.43
For additional specificity, the glucan in the GeRPs targets M
cells in intestinal Peyer’s patches, a specialized cell found in
the intestinal epithelium that transports antigens found in the
lumen of the GI tract to the immune system.44 The M cells
phagocytose the GeRPs via the beta 1,3-d-glucan receptor
pathway, and once intracellular, the acidic pH of the phagosomes allows siRNA to escape through the porous outer
wall of the glucan particle. In vitro experiments with peritoneal exudate cell macrophages exposed to GeRPs showed a
70–80% knockdown of the Map4k4 mRNA and with no effect
on mRNA levels with phosphate-buffered saline or scrambled siRNA controls. When these macrophages were stimulated with lipopolysaccharide (LPS) and treated with GeRPs
containing siRNA to MAP4k4, TNF-α mRNA levels were decreased 40% and TNF-α protein expression decreased 50%
compared with controls. In vivo, mice orally gavaged a solution of Map4k4 siRNA containing GeRPs showed an 80%
decrease in TNF-α and IL-1β, another inflammatory cytokine,
protein expression compared with scrambled siRNA. GeRPs
containing either Map4k4 or one of two other types of TNF
siRNA decreased the lethality associated with LPS injection.
Damaging reactive oxygen species (ROS) are one of the
components released by inflamed cells in the intestine.
Wilson et al.45 developed nanoparticles with the polymer
poly-(1,4-phenyleneacetone dimethylene thioketal) (PPADT)
designed to degrade in the presence of ROS and release
their siRNA payload (Figure 1b). In in vitro studies, macrophages were treated with LPS to replicate inflammation and
release ROS. The macrophages exposed to LPS demonstrated increased uptake of fluorescent dye-loaded PPADT
nanoparticles compared with macrophages without stimulation, indicating that these nanoparticles were responsive
to ROS. Next, either Cy3 fluorescently tagged siRNA or
TNF-α siRNA were complexed with the cationic lipid 1,2dioleoyl-3-trimethylammonium-propane, known to improve
siRNA entrapment efficacy.46,47 The siRNA was loaded into
PPADT nanoparticles via an oil-in-water single-emulsion process. In mice with DSS-induced colitis, Cy3-siRNA PPADT
nanoparticles given via oral gavage effectively localized to
the sites of intestinal inflammation. To evaluate the nanoparticle’s ability to control inflammation, DSS colitis mice were

given TNF-α siRNA PPADT nanoparticles via oral gavage at
either 2.3 mg/kg/day or 0.23 mg/kg/day of TNF-α siRNA for
6 consecutive days beginning the same day as induction of
colitis. Mice given the higher dose exhibited a 10-fold decrease in TNF-α mRNA levels (3-fold decrease at the lower
dose) in the colon compared with controls, a finding not
seen with size-matched and charge-matched poly lactic-coglycolic acid (PLGA) nanoparticles. Inflammatory cytokines
IL-6, IL-1, and interferon-γ mRNA levels were also decreased
in the PPADT nanoparticle treatment group. Clinical improvements were noted in DSS-colitis mice treated with PPADT
nanoparticles, namely less weight loss, lower MPO (a marker
of neutrophils in the intestine) levels, and improved histological appearance compared with controls. This group directly
compared their nanoparticles to the GeRPs of Aouadi et al.42
Each respective particle was loaded with the lower dose of
0.23 mg/kg/day of TNF-α siRNA. The PPADT nanoparticles
showed superior performance in decreasing TNF-α mRNA
levels and clinical signs of disease (less weight loss, lower
MPO, and improved histology) over the GeRPs, an effect
the authors credit to the targeting capabilities of the PPADT
nanoparticles.
Further exploring the use of cationic polymers, Laroui
et al.48 compared the protective ability of PEI/siRNA polyplexes with chitosan/siRNA polyplexes. Chitosan, a biopolymer derived from chitin in marine organisms, is positively
charged at pH lower than 6.549 and has known mucoadhesive properties.50 After incubation with RNase A, the polyplexes both conferred complexation and protection, but
PEI outperformed chitosan in both parameters. The group
synthesized polylactide (PLA) nanoparticles with PEI/siRNA
polyplex composing the internal phase (Figure 1c). The
nanoparticles were coated with poly vinyl alcohol (PVA) to
help prevent electrostatic aggregation. Varying PLA concentrations (5, 10, 15, and 20 g/L were investigated) produced
varying size and electrostatic charges of the nanoparticles. Compared with chitosan-complexed or uncomplexed
siRNA, PEI/siRNA polyplexes had a more prolonged kinetic
release profile in phosphate-buffered saline. After 30 minutes, 70% of the PLA/PVA nanoparticles with PEI/siRNA
polyplexes remained loaded with siRNA compared with
50% of the chitosan/siRNA polyplexes and 20% of nanoparticles loaded with uncomplexed siRNA. Uptake of PLA/
PVA nanoparticles containing fluorescently tagged siRNA/
PEI into macrophages in vitro demonstrated an increasing
fluorescent signal with increasing PLA concentration. PLA/
PVA nanoparticles containing PEI/siRNA polyplexes outperformed lipofectamine and PLA/PVA nanoparticles containing chitosan/siRNA polyplexes in transfection efficiency into
macrophages. Additionally, lipofectamine caused macrophage activation, whereas the nanoparticles did not. PEI/
siRNA complexed nanoparticles were encapsulated in an

Figure 1 Simple schematics of the discussed polymer oral siRNA drug delivery systems. (a) Aouadi et al.42 (b) Wilson et al.45 (c) Laroui
et al.48,55 (d) Xiao et al.51 (e) Xiao et al.52 (f) Xiao et al.60 (g) Xiao et al.65 (h) Laroui et al.71 (i) He et al.84 (j) Kriegel and Amiji.78 (k) Attarwala
et al.81 (l) Ballarín-González et al.83 (m) Knipe et al.86 DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DEAEMA-co-tBMA,
2-(diethylamino)ethyl methacrylate-co-tert-butyl methacrylate; Fab’, antigen-binding fragment; HA, hyaluronic acid; IL, interleukin;
NP, nanoparticle; p(CBA-bPEI), p(cystamine bisacrylamide-polyethylenimine); PCL, polycaprolactone; PEI, polyethylenimine; PEG,
poly(ethylene glycol); PLA, polylactide; PLGA, poly lactic-co-glycolic acid; p(MAA-co-NVP), poly(methacrylic acid-co-N-vinyl-2pyrrolidone); PPADT, poly-(1,4-phenylaeneacteone dimethylene thioketal); PVA, polyvinyl alcohol; TCC, trimethyl chitosan-cysteine;
TG2, transglutaminase 2; TNF-α, tumor necrosis factor alpha; TPP, tripolyphosphate; tRNA, yeast transfer RNA.
Clinical and Translational Science
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alginate/chitosan hydrogel and delivered via gastric lavage
to mice for 4 days prior to an intraperitoneal injection of LPS
to initiate inflammation. The alginate/chitosan hydrogel was
designed to collapse in colonic pH conditions providing a
targeted delivery of the nanoparticles to the lower GI tract.
TNF-α protein levels were significantly lower in the blood and
colonic tissue of siRNA pretreated mice compared with nontreated controls (blood: 1,751.5 pg/mL vs. 2,084.5 pg/mL;
colon tissue: 7.5 pg/mL vs. 136.2 pg/mL; and liver tissue:
117.1 pg/mL vs. 154.2 pg/mL) but not significantly lower in
the liver, which the authors believe suggests that the action
of silencing is targeted and localized to the GI tract with limited systemic effect.
The same group investigated other targets of intestinal
inflammation, such as CD9851 and mannose receptors.52
The cell surface transporter CD98 is upregulated in intestinal epithelial cells by proinflammatory cytokines in IBD.53,54
CD98 siRNA was complexed with PEI and loaded into a PLA
nanoparticle matrix and covered in PVA similar to the previously discussed study55 (Figure 1c). When encapsulated
in the alginate/chitosan hydrogel and delivered orally daily
during induction of DSS colitis, the treated mice showed
significantly less weight loss: 10% loss of body weight in
controls vs. 3% loss of body weight in siRNA-treated mice.
MPO levels were attenuated but not normalized. CD98
mRNA levels were decreased threefold, and expression levels of inflammatory cytokines IL-1β, IL-6, and keratinocidederived cytokine (KC) were decreased 5–15-fold. Treated
mice showed improved histology and visual inspection
with colonoscopy marking CD98 as a reasonable target for
siRNA therapy for IBD.
In an attempt to improve the CD98 siRNA delivery, Xiao
et al.51 fabricated a new polymer with single chain CD98 antibody attached to a nanoparticle composed of polyethylene
glycol (PEG)-urocanic acid-modified chitosan (Figure 1d).
PEG-functionalized nanoparticles have previously demonstrated superior ability to “slip” through mucous in the GI
tract,56 whereas chitosan, when complexed with urocanic
acid, bears an imidazole ring that assists in endosomal rupture to release siRNA via the “proton sponge” mechanism.57
This novel polymer was combined with PEI complexed siRNA
to CD98 to form nanoparticles that self-assemble to have
the antibody on the surface. In vitro studies in bone marrowderived macrophage cultures demonstrated that CD98 functionalized nanoparticles effectively increased cellular uptake
(1.7-fold and 1.3-fold at 3 and 6 hours, respectively) compared with nonfunctionalized nanoparticles. Ex vivo studies
using murine DSS colitis tissue exposed to dye-labeled siRNA
demonstrated large amounts of nanoparticles were taken up
by inflamed intestinal epithelial cells, and, to a lesser extent,
macrophages, after 6 hours. Using Colon-26 cells and RAW
264.7 cells (murine macrophages) depleted of CD98, transfection efficiency of the CD98 antibody nanoparticles was
decreased 42.8% and 59.8%, respectively, ostensibly due
to the loss of targeting from the nanoparticle antibodies. To
broaden applicability, the in vivo studies used two models of
colitis: the DSS colitis mouse, which models ulcerative colitis
and recombinase activating gene-1-deficient mice injected
with CD4+ CD45RBhigh T cells used to replicate chronic colitis more consistent with Crohn disease.26 The recombinase
Clinical and Translational Science

activating gene-1–deficient mice treated with alginate/chitosan hydrogel containing CD98 antibody–coated, CD98
siRNA–loaded nanoparticles (1 mg/kg siRNA) showed significantly less weight loss at week 9 compared with control
or treatment control (scrambled siRNA) groups. MPO activity
was decreased 65.7% compared with the untreated group.
CD98 mRNA was decreased, as well as nontargeted, downstream cytokines: mRNA expression of TNF-α, IL-6, and
IL-12 decreased 59.9%, 80.4%, and 31.8%, respectively. In
the DSS colitis model, mice in the treatment group showed
50% less body-weight loss, 47.7% decrease in CD98 mRNA
levels, and significant decreases in TNF-α, IL-6, and IL-12
mRNA expression (26.0%, 81.2%, and 71.2%, respectively).
Due to the polygenic, complicated physiology of IBDs,58
treatment regimens are frequently polypharmacologic to
attempt to improve efficacy while minimizing adverse effects.59 Thus, combining multiple drugs into one delivery
system could improve efficacy while simplifying dosing.
After showing that delivery of siRNA to CD98 was successful in downregulating inflammation, Xiao et al.60 looked to
codeliver curcumin, a known anti-inflammatory agent,61with
CD98 siRNA (Figure 1e). The two components were captured within PLGA nanoparticles and then coated with chitosan. The surface of these nanoparticles was functionalized
with hyaluronic acid to target the colon.62–64 The hyaluronic
functionalized combination therapy nanoparticles released
44.9% and 57.6% of the CD98 siRNA and curcumin, respectively, over 24 hours, and 68.8% and 89.7% of the
CD98 siRNA and curcumin, respectively, over 72 hours. In
vitro modeling of inflammation used Caco-2 cells (an immortalized human colon cancer cell line) in the apical chamber of a transwell culture and RAW 264.7 macrophages in
the basolateral chamber. Macrophage exposure to LPS in
the basolateral chamber released inflammatory cytokines
causing damage to the Caco-2 monolayer and allowing fluorescein isothiocyanate (FITC)-dextran placed in the apical
chamber to flux through to the basolateral side. Damage to
the layer was quantified by measuring fluorescence in the
basolateral chamber supernatant. Addition of the two-drug
nanoparticles (10 ng/mL of CD98 siRNA and 8.2 μM curcumin) decreased the flux of fluorescence signal, indicating
mucosal protection of the epithelial layer. Either drug on its
own did not have a significant effect suggesting the synergistic efforts of the two-drug combination was required to
achieve mucosal protection. The two-drug combination decreased CD98 and TNF-α mRNA expression after 24 hours
of exposure in vitro, although this effect did not persist in
CD98 mRNA at 48 hours. The nanoparticles were then encapsulated in alginate/chitosan for oral gavage in mice. In
these in vivo studies, the dual-loaded nanoparticles showed
superior performance at decreasing clinical symptoms of
DSS colitis compared with either drug alone. Mice treated
with hyaluronic acid (HA)-functionalized, dual drug nanoparticles only lost ~ 5% of body weight compared with nearly
15% in untreated colitis controls. Fecal lipocalin 2 levels (a
marker of intestinal neutrophils) in mice treated with HAfunctionalized, dual drug nanoparticles were one-third of the
elevation of untreated colitis controls, and MPO levels were
approximately one-fourth of untreated colitis controls. CD98
mRNA expression was decreased in all treatment conditions
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(single/dual drug and +/−HA-functionalized nanoparticles) by 59.2–73.8%, but the HA-functionalized, dual-drug
nanoparticles were the best performers at decreasing both
CD98 mRNA and TNF-α mRNA expression.
This group also tried combination therapy of TNF silencing and IL-22.65 IL-22 is a pro-healing cytokine that helps
with proliferation and survival of damaged epithelial cells,
regenerating goblet cells to rebuild the protective mucous
layer, and stimulating Paneth and epithelial cells to secrete
antimicrobial peptides.66–68 Mice treated with anti-TNF antibody experienced decreased levels of IL-22 demonstrating
that a common pathway was likely depleting this protective cytokine during TNF-α targeting with biologic therapy.
A PLGA nanoparticle was used to encapsulate the IL-22
and TNF-α siRNA complexed with spermidine (Figure 1f).
The surface of these nanoparticles was functionalized with
galactose for macrophage targeting69 and in vitro studies confirmed that galactose-functionalized nanoparticles
more efficiently transferred siRNA to the cytoplasm of RAW
264.7 macrophages. LPS stimulated macrophages treated
with galactose-functionalized nanoparticles containing
TNF-α siRNA prior to insult maintained decreased levels of
TNF-α compared with controls and maintained these decreased levels after 96 hours. To demonstrate the mucosal healing ability of IL-22, Caco-2 monolayers were grown
to confluence and an electrical injury applied to damage
the cells and disrupt tight junctions. The subsequent addition of IL-22 at either 50 or 100 ng/mL sped up the time to
recover resistance in a dose-dependent fashion. The two
treatments (galactose-functionalized nanoparticles containing siRNA and IL-22) were encapsulated in the alginate/
chitosan hydrogel and orally gavaged to DSS colitis mice.
The combination drug group demonstrated the smallest
body weight loss among all groups and showed the quickest body weight recovery after treatment. Mice receiving
the combination therapy showed no significant difference
from healthy controls in TNF-α protein expression, nor clinical measures, such as colon length, MPO levels, and histological score.
Xiao et al.52 also investigated targeting mannose receptors exclusively expressed on macrophages. The novel
bioreducible polymer p(Cystamine bisacrylamide-branched)
PEI was designed to degrade in the reducing environment
of the cell for sustained release of TNF-α siRNA. The polymer chains were coupled with mannose residues via a
PEG linker and the entity termed PPM (Figure 1g). PPM
nanoparticles were formed with the ionic crosslinker sodium
tripolyphosphate, which was chosen to avoid toxicities associated with covalent crosslinkers.70 The mannose modified nanoparticles showed significantly increased cellular
uptake in RAW 264.7 cells compared with controls (p(Cystamine bisacrylamide-branched) PEI with only PEG and no
mannose). This effect was mitigated in media with enough
free mannose to saturate receptors and negate the effect of
mannose receptor targeting. The mannose-coated nanoparticles showed a decrease in TNF-α protein expression similar to commercially available oligofectamine but with twofold
less contained siRNA. Ex vivo studies with the colon from
a DSS colitis mouse model showed preferential uptake by
mannose receptor bearing macrophages over intestinal

epithelial cells when incubated for 12 hours with 200 nM
siRNA nanoparticles.
Macrophages are less prevalent in the GI tract than
other cell types but increased in areas with inflammation.71
Immunoglobulin G antibody can be partially digested to remove the Fragment crystallizable (Fc) variable domain portion
to yield the antigen-binding Fab’ fragments. Reducing the
immunoglobulin to just the Fab’ portion decreases its interaction with the immune system.72 F4/80 is a murine homolog
of Epidermal growth factor (EGF)-like module-containing mucin-like hormone receptor-like 1 and a marker of mouse macrophages.73 Laroui et al.71 made a PLA-PEG block copolymer
nanoparticle with the Fab’ portion of an antibody to F4/80
attached to the PEG portion via a maleimide reactive functional group and loaded them with TNF-α siRNA complexed
with PEI (Figure 1h). The Fab’ coating prevented aggregation of the nanoparticles through intrinsic repelling forces,
which significantly decreased aggregation-induced toxicity.
To show that the Fab’ portion remains upright and functional,
the Fab’-coated nanoparticles were affixed to a gold chip
and exposed to flowing Caco-2 cells and RAW 264.7 macrophages. The RAW 264.7 macrophages bound to the Fab’bearing nanoparticles in a dose-dependent manner, whereas
significantly lower binding was seen with Caco-2 cells. In cultured RAW 264.7 murine macrophages as well as U937 and
THP-1 human macrophages, the Fab’-coated nanoparticles
were more frequently endocytosed compared with uncoated
nanoparticles. Additionally, when RAW 264.7 macrophages
were exposed overnight to the various nanoparticle conditions and then treated with LPS to induce inflammation,
TNF-α mRNA was significantly decreased in cells treated with
Fab’ bearing nanoparticles compared with controls, including lipofectamine. When encapsulated in alginate/chitosan
hydrogel and delivered orally prior to inducing DSS colitis in
mice, the mice who consumed Fab’-coated nanoparticles
had improved histological appearance, a decrease in weight
loss (6% compared with 25% in untreated controls), and
lower MPO levels (0.07 unit/μg of total colon protein for mice
that received Fab’-bearing TNFα siRNA-loaded nanoparticles, compared with 22 units/μg of total colon protein in mice
receiving scrambled controls). Although more moderate,
there was also a significant improvement of the weight loss
and MPO levels when comparing Fab’-coated nanoparticles
vs. TNF-α siRNA nanoparticles with no coating (weight loss
6% and 9%, respectively, and MPO activities of 0.07 and 0.1
unit/μg of total colon protein, respectively).
He et al.74 developed another polymer-only based system with a trimethyl chitosan-cysteine (TCC) nanoparticle
modified with mannose (Figure 1i). The rational use of the
polymer was to facilitate the uptake of the nanoparticles into
the epithelial cells through two mechanisms. First, trimethylated chitosan provides sufficient positive charges for the
nanoparticles to be attracted to the negatively charged cell
membranes. The second, the cysteine conjugation presented a free sulfhydryl group to form disulfide bonds with
the mucin glycoproteins in the mucous.75,76 A 2′-O-methyl
modification of siRNA duplexes helped confer stability of
the siRNA. Rather than PEI, siRNA was able to be captured
by ionic gelation using various molecular weights of TCC
and tripolyphosphate as a crosslinker.77 TCC nanoparticles
www.cts-journal.com
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made with 200 kDa chitosan outperformed other molecular
weight chitosan nanoparticles in vitro by suppressing TNF-α
mRNA expression to 66% and the TNF-α protein expression
to 70% of expected based on controls. In vivo work interestingly demonstrated that oral gavage of these trimethylated
chitosan nanoparticles was more efficacious than peritoneal
injection (expressing 40–50% vs. 60% of expected TNA-α
mRNA, respectively) despite the hostile environment of the
GI tract possibly due to more efficient absorption via intestinal enterocytes and M cells or transfection of gut-associated macrophages in Peyer’s patches.
For added layers of protection and control of the degradable siRNA cargo, Kriegel et al. and Kriegel and Amiji7,78
used a nanoparticle-in-microsphere oral system (NiMOS;
Figure 1j) to deliver nucleic acids to the GI tract. First, they
fabricated gelatin nanoparticles containing TNF-α siRNA.
Gelatin is used to entrap the siRNA rather than complexing
it to positively charged substances or adsorbing it to a surface to allow for easier release. These nanoparticles were
then embedded in polycaprolactone microspheres between
2 and 4 μm in diameter. DSS colitis mice were dosed with
NiMOS every other day starting on day 3 after induction of
colitis for a total of 3 doses (1.2 mg/kg). The NiMOS system
showed a significant decrease in TNF-α mRNA and TNF-α
protein expression on day 10 after colitis induction. The
NiMOS system containing scrambled siRNA also showed
some efficacy in decreasing TNF-α protein. However, when
examining clinical factors of colon histology and bodyweight loss, the NiMOS with TNF-α siRNA performed better than scrambled or empty NiMOS. Additionally, they
examined an NiMOS combining TNF-α siRNA and Cyclin
D1 siRNA. Cyclin D1 is a cell-cycle regulating molecule
known to be upregulated in colonic inflammation,79 and
Cyclin D1 siRNA has been shown to reverse colitis in mice
when delivered via intravenous nanoparticles.80 Using a
similar gelatin and polycaprolactone NiMOS, the combination of TNF-α and Cyclin D1 gene silencing was showed
to be superior to TNF-α silencing alone in suppressing
TNF-α and Cyclin D1 mRNA levels, limiting body weight
loss, MPO levels, and histologic appearance. NiMOS treatment groups also showed a decrease in proinflammatory
cytokines IL-1α, IL-1β, IL-5, and IL-17, and chemokines
monocyte chemotactic protein-1, MIP-1α, and granulocyte
macrophage colony-stimulating factor. Silencing of Cyclin
D1 was specific—no silencing of TNF-α was noted when
only Cyclin D1 siRNA was administered. Overall, the strongest reduction in proinflammatory markers was with Cyclin
D1 siRNA alone, which suggests its overall potency and
subsequently decreased potency when diluted with TNF-α
siRNA in competition for space in the nanoparticle.
Although most oral siRNA silencing has been directed at
IBD, Attarwala et al.81 investigated using similar methods
to target celiac disease. Celiac disease is an inflammatory
condition affecting the small intestine and leading to weight
loss, abdominal pain, anemia, vitamin deficiencies, poor
growth in children, and infertility. Celiac disease is caused
by T-cell mediated response to deamidated gluten peptides modified by the enzyme transglutaminase 2 (TG2).
These glutens are found in wheat, rye, and barley, and the
usual treatment is to avoid these in the diet. IL-15 activates
Clinical and Translational Science

intraepithelial lymphocytes, which is a hallmark finding in
celiac histology.82 This group hypothesizes that nanoparticle-delivered siRNA blocking TG2 and IL-15 production
could attenuate the symptoms of celiac disease. IL-15 and
TG2 siRNA were combined in gelatin nanoparticles for an in
vitro study using Caco-2 cells (Figure 1k). Although the uptake of these nanoparticles was less than the commercially
available lipofectamine, the TG2 and IL-15 siRNA could be
found associated with RISC in the cells for a longer time
period after administration (2.5–2.2-fold longer at 72, 96,
and 120 hour timepoints). Whereas gelatin nanoparticles
produced only a maximum of 60% silencing efficiency of
TG2 mRNA (less than the >80% seen with lipofectamine),
again the effect was sustained at the later timepoints (gelatin
nanoparticles 40% TG2 silencing, lipofectamine TG2 levels
back at baseline at 96 hours). Similar results were noted with
IL-15. Incubating Caco-2 and J774A.1 (murine macrophage)
cells with the immunogenic α-gliadin p31–43 peptide served
as an in vitro celiac disease model increasing the production of IL-15 and TG2 mRNA by 3.5-fold and 1.75-fold, respectively. Gelatin nanoparticles containing IL-15 siRNA
suppressed IL-15 mRNA production but not TG2 mRNA
production. Similarly, gelatin nanoparticles containing TG2
siRNA suppressed TG2 mRNA but not IL-15 mRNA. In the
J772A.1 cells, IL-15 siRNA nanoparticles were more effective at decreasing TNF-α and INF-γ levels, when compared
with TG2 siRNA nanoparticles. Nanoparticles containing the
combination of TG2 and IL-15 siRNA produced the greatest
suppression of TNF-α and INF-γ protein levels.
Most studies measured the silencing potential of siRNA
formulations (i.e., by measuring TNF-α mRNA or protein)
and extrapolate siRNA protection from these data. In an attempt to directly measure the ability of chitosan nanoparticles to protect siRNA in vivo, Ballarín-González et al.83
made chitosan nanoparticles with unmodified siRNA
(Figure 1l) via self-assembly (similar to the self-assembly
method evaluated by He et al.84). Previously, the charge
ratio between amino groups of chitosan and phosphate
groups of siRNA (N:P ratio) had been determined to affect the stability and gene silencing ability in vitro of
chitosan nanoparticles.85 Chitosan nanoparticles with
various N:P ratios (5, 20, 60, and 120) were fabricated to
determine the ratio’s effect on siRNA protection in vivo.
In vivo stability was measured by administering chitosan
nanoparticles loaded with siRNA by oral gavage and
measuring siRNA levels via northern blot and quantitative
polymerase chain reaction in intestinal tissue after 1 and
5 hours. Significant degradation of naked siRNA was seen
in all groups, but the chitosan nanoparticle–treated mice
intestine contained relatively more intact siRNA (levels increased 3.4-fold in the proximal small intestine at 5 hours
and >11-fold in the distal small intestine at 5 hours and
colon at 1 hour). Overall, the higher N:P ratio particles
bore a trend toward stability. Higher particle–particle interactions in the higher N:P ratio are hypothesized to contribute to stability. Kidneys and spleens harvested from
animals treated with siRNA-containing nanoparticles all
had detectable siRNA at all N:P ratios 1 hour after gavage
demonstrating systemic distribution of siRNA from oral
delivery.
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To navigate the many intestinal barriers, Knipe et al.86
took a multistep approach to engineer a microencapsulated
nanogel (Figure 1m). First, polycationic nanogels (nanoparticles formed from a hydrophilic gel) were fabricated from
2-(diethylamino) ethyl methacrylate. These nanogels swell in
the low endosomal pH, increasing their hydrodynamic diameter and facilitating siRNA escape into the cytosol. The size
of the gels (~100 nm) is designed to interact with inflamed intestinal epithelial cells and macrophages. PEG grafts on the
nanogels increase mucosal penetration. The nanogels were
then complexed in a microgel made of anionic poly(methacrylic acid-co-N-vinyl-2-pyrrolidone) and cross-linked with a
trypsin degradable peptide. The microgels are complexed
in low gastric pH but swell when they reach the higher pH
of the small intestine. The peptide crosslinker is designed
to be resistant to pepsin enzymes in the stomach, whereas
trypsin in the small intestine cleaves these bonds releasing
the nanogels. In vitro studies exposed RAW 264.7 murine
macrophages to nanogels, degraded microgels containing
nanogels (to mimic intestinal passage), and lipofectamine
controls. The nanogels and degraded microgels decreased
TNF-α levels with an efficacy similar to lipofectamine (all
around ~ 40–50% silencing) with limited toxicity, although
2.5× more siRNA was used in the nanogels to achieve the
same level of silencing. Nanogels alone outperformed the
degraded microgels, which the authors hypothesize may be
due to electrostatic interactions between the components.
Lipid systems
Cationic liposomes have been the standard for transfection of siRNA. Commercially available transfection vectors, such as lipofectamine, utilize these liposomes. The
liposome phospholipid bilayer allows it to cross the cell
membrane to deliver its hydrophilic core of siRNA to the
cytoplasm.39 Early liposome delivery methods failed to
show ability for systemic gene silencing but were successful locally.87 However, liposome delivery is complicated by
concerns for toxicity88 and requires improvement in efficacy. Ball et al.89 made lipoid nanoparticles (LNPs) made
of amphiphilic lipid-like materials, which when complexed
with cholesterol, distearoyl-sn-glycerol-3-phosphocholine, and PEG-lipid form the nanoparticles. Three lipidoids
were chosen from a library of synthesized lipidoids90 for
their potential to target intestinal epithelial cells. One
LNP, 306O13, was then chosen for its ability to silence
the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in Caco-2 cells in vitro.91 Further
studies demonstrate that 306O13 LNPs were efficient at
gene silencing across a pH range of 1–9 in vitro in HeLa
cells, promising for exhibiting stability across the range of
pH present in the GI tract. After the LNPs underwent simulated GI digestion conditions, pepsin and bile salts were
found to decrease LNP GAPDH silencing in Caco-2 cells.
Silencing efficacy was relatively unaffected by pancreatin
or low pH (1.2). Mucin at a 2% w/v concentration in Caco-2
cell buffer was also found to drastically reduce silencing
potential (90–40%). LNPs stay in the mouse GI tract for
8 hours after delivery, and fluorescently labeled siRNA was
found in mouse intestinal cells; however, the gene silencing
of GAPDH in vivo was not statistically significant.89 The low

in vivo efficacy may be due to spotty uptake. Therefore,
working on uniform delivery across more epithelial cells
may yield better results.
The toxicity of synthetic cationic liposomes makes the
search for naturally sourced lipid delivery vehicles a promising field. Zhang et al.92 investigated nanoparticles fabricated
from lipids harvested from ginger, termed ginger-derived
lipid vehicles (GDLV). After extracting the lipids from blended
ginger through a series of fractionating processes, the lipids were loaded with CD98 siRNA. These GDLVs demonstrate effective gene silencing in vitro in Colon-26 cells and
RAW 264.7 cells. CD98 siRNA carried by GDLVs effectively
inhibited the expression of CD98 mRNA by 20.2 ± 5.1%
and 21.4 ± 6.2% for 24 and 48 hours in colon-26 cells;
66.1 ± 12.9% and 43.0.4 ± 3.0% for 24 and 48 hours in
RAW cells, a silencing effect equivalent to that of lipofectamine 2000. After two oral administrations of the GDLV to
mice, there were significant decreases of CD98 expression
in the ileum and colon. In addition to biocompatibility, these
nanoparticles are more economically produced than synthetic nanoparticles.
RECTAL DELIVERY SYSTEMS
Topical therapy to the intestine can also be delivered
rectally. Rectal therapy (through enema or suppository)
can only cover a limited area of the lower intestine; however, rectal administration allows bypass of many of the
complicating factors of topical intestinal delivery, such as
lower gastric pH, digestive enzymes in the small intestine, and need for colon targeting. Occasionally, rectal
formulations can be applied to the entire effected area
in ulcerative colitis as the disease can be isolated to the
rectum. 29
Building off their success at increasing transdermal
permeability using ultrasound,93 Schoellhammer et al.94
investigated using similar ultrasound methods to increase
the efficacy of siRNA delivery in mouse colons. TNF-α
siRNA in water was administered rectally and then exposed to two pulses of 40 kHz ultrasound via an internal
probe. Mice treated with the ultrasound showed a 7–8-fold
increase in silencing efficiency of TNF-α compared with
controls.
Modified cyclodextrins (naturally occurring oligosaccharides) have also been used to protect siRNA payload
for rectal administration. McCarthy et al.95 synthesized an
amphiphilic cyclodextrin complexed with siRNA via “click”
chemistry. TNF-α siRNA complexed with cyclodextrin (CD.
TNF-α) administered to RAW264.7 macrophages resulted in
a decrease in TNF-α as well as the inflammatory cytokine
IL-6. CD.TNF-α was delivered rectally to DSS colitis mice
in two divided doses 2 and 4 days after induction of colitis. Mice treated with CD.TNF-α showed improvement of
clinical factors, such as weight loss and blood in stool, but
these results were not significant. However, TNF-α and IL-6
mRNA levels were decreased significantly in CD.TNF-α mice
compared with controls. Interestingly, they showed a more
profound decrease in TNF-α mRNA in the proximal colon,
possibly due to differing immune cell populations found in
this area of the colon.
www.cts-journal.com
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Naturally derived components also hold promise for rectal
delivery. Calcium phosphate (Ca-P) is an inorganic material
found in bone, teeth, and tendons. Its biological compatibility makes it an excellent candidate for nanoparticle vector
delivery of siRNA. Frede et al.96 fabricated Ca-P nanoparticles with siRNA adsorbed to the surface and encapsulated
in PLGA. PEI added as an outer layer gives the nanoparticle
a positive charge to aid in cell uptake. Ca-P nanoparticles
contained siRNA to target TNF-α, keratinocide-derived cytokine, or interferon gamma-induced protein 10 (IP-10). In vitro
studies using the jejunum-derived MODE-K cell line demonstrated efficacy at each of these nanoparticles to decrease
their respective target’s mRNA expression (30% decrease
with IP-10, 50% with TNF-α or KC). An innovative murine
colonic organoid model was used for in vitro studies. The
organoids were exposed to nanoparticles in their crypt form
immediately after plating and prior to forming a closed epithelial barrier. Over 24 hours, 30% of the crypt cells took up
fluorescent nanoparticles. Using the same exposure methods as the MODE-K cells, TNF-α, KC, and IP-10 mRNA were
all decreased by about 50% in the colonic crypt organoids.
In vivo, DSS colitis mice received rectal doses of a mixture of
all 3 siRNA Ca-P nanoparticles on days 2–5 after induction
of colitis. The inflamed colon took up nanoparticles at an
increased rate compared with an uninflamed colon, particularly in the intestinal epithelial cells and mesenteric lymph
nodes. The relative expression of TNF-α mRNA in the colon
was reduced by 40%, whereas KC and IP-10 expression
was diminished by up to 50%. Mice treated with siRNA containing Ca-P nanoparticles fared better than controls clinically with significantly less body weight loss, lower levels
of blood in stool and diarrhea, higher hematocrit levels, and
less change in colon length. Interestingly, dendritic cells, T
cells, intestinal epithelial cells, and macrophages all took up
fluorescently labeled nanoparticles, but only T cells and epithelial cells showed a decrease in TNF-α expression when
active siRNA nanoparticles were administered.

dissection was performed in juvenile pigs immediately
followed by a single injection of CHST15 siRNA into the
resultant ulcer. At endoscopic examination on day 7, the
esophagus grossly appeared less strictured with measurably less mucosal contraction. Histologically, cellular deposition of fibroblasts and myofibroblasts, cell types present
in strictured tissue, was decreased in the treated animals.
Additionally, the analyzed tissue showed decreases of
CHST15, TGF-β, and collagen-1 mRNA (~30% of positive
control for all; 4, 3, and 5 times increase from negative control, respectively).
Kim et al.103 evaluated topical treatment to the esophagus for fibrosis and stricturing caused by stent placement. Immediately after placing a self-expanding metal
stent in the esophagus of rats, they inflated two balloons
in the esophagus lumen: one proximal and one distal to
the stent (Figure 2). Solution containing siRNA to matrix
metalloproteinase-9 (a mediator of injury-induced proliferation) complexed with cholesteryl oligo-d-arginine was
indwelled between the balloons for 30 minutes for a single
treatment. Three weeks after stent placement, the animals
treated with siRNA showed fewer gross anatomic changes
of stricturing compared with a stent-only control group.
Additionally, the siRNA group exhibited decreased levels
of matrix metalloproteinaise-9 compared with the stentonly group as well as decreased granulation tissue when
examined histologically.

ESOPHAGEAL DELIVERY SYSTEMS
The esophagus is the most proximal part of the GI tract and
is responsible for transit rather than digestion or nutrient
uptake. Inflammatory diseases, cancer, or injury are common causes of esophageal pathology.97 Stricturing is a frequent complication associated either with organic disease
or iatrogenic injury that can lead to dysphagia, odynophagia, and food impaction.98,99 Local applications of siRNA
to the esophagus have been investigated to decrease the
effects of stricturing. Sato et al.100 looked to prevent complications from endoscopic submucosal dissection, a procedure performed to remove esophageal carcinoma, by
application of carbohydrate sulfotransferase 15 (CHST15)
siRNA. Because the procedure requires significant tissue
manipulation, inflammation afterward commonly leads to
mucosal contraction.101 CHST15 is a transmembrane Golgi
protein, which has been shown to be involved in fibrosis in
mouse colitis and myocarditis. CHST15 produces sulfated
disaccharide units of chondroitin sulfate into the extracellular matrix and is thought to contribute to the fibrosis
after resection.102 A semicircular endoscopic submucosal
Clinical and Translational Science

Figure 2 Schematic of double-balloon catheter in esophagus.
After stent deployment, siRNA containing fluid is instilled
between the two inflated balloons. Kim et al.103
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CONCLUSION AND FUTURE DIRECTIONS
RNA interference therapy for intestinal diseases continues to hold great promise, and progress has been made
over the last decade to develop local GI tract therapies.
Synthetic siRNAs can be fabricated with any sequence and
chemical modifications for stability are possible.
The strategies mentioned in this paper target the colon or
esophagus but inflammatory conditions, such as IBD, postoperative strictures, cancers, or immune enteropathies, can
affect any site along the GI tract. Local delivery of oral siRNA
continues to require significant protection from degradation,
especially if attempting to target the distal GI tract orally.
Areas of rapid transit, such as the esophagus, also pose
a targeting problem when working toward oral therapies.
Although methods of polymer or liposome encapsulation
improve dose delivery to sites, these methods further complicate manufacturing and increase costs. To keep the benefits of oral therapy’s simplicity and lower cost, researchers
will need to continue to work toward streamlining methods
and improving protection to decrease siRNA doses.
As our pathophysiologic knowledge of intestinal diseases
expands, new potential target genes emerge. However, the
common GI diseases these new drug-delivery methods
are attempting to treat (IBD, celiac, etc.) are complex, multigenic processes that have no known single target gene.
Treating IBD with anti-TNF and anti-integrin biologics is not
universally successful and patients frequently are required to
change medications due to lack of efficacy.104 Further studies into the causes of these diseases with bring new gene
targets and new challenges for delivery. Expanding into
other, less common diseases in need of better treatments
(e.g., eosinophilic esophagitis) will expand possibilities for
other groups of patients. Although siRNA therapy continues
to encounter challenges, each successful maneuver around
a barrier brings the field closer to successful therapies for
patients and decreased burden of disease.
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